Novo Nordisk Shares Face Pressure After Clinical Trial Disappointment

Novo Nordisk's obesity drug candidate CagriSema failed to prove non-inferior to Eli Lilly's tirzepatide in a head-to-head trial, causing a stock downgrade and share price drop.

Investor confidence in Novo Nordisk's competitive standing within the lucrative obesity drug market has been shaken. The pharmaceutical giant encountered a significant setback when its promising candidate, CagriSema, failed to meet expectations in a head-to-head clinical comparison against a key rival from Eli Lilly.

Head-to-Head Trial Falls Short of Primary Goal

The focus of the disappointment is the Phase 3 clinical investigation known as REDEFINE 4. This open-label study, which ran for 84 weeks and involved 809 participants with obesity, was designed to demonstrate that CagriSema was at least as effective as Eli Lilly's tirzepatide, the active ingredient in its treatments.

The data revealed that patients on CagriSema achieved an average weight loss of 23%. While substantial, this result trailed the 25.5% reduction recorded for those taking tirzepatide. Consequently, the trial did not achieve its primary endpoint of proving non-inferiority or superiority for Novo Nordisk's drug candidate. The company noted that the most common adverse events were gastrointestinal in nature, with most being characterized as mild to moderate.

Market Reaction and Analyst Downgrade

Direct comparative trials in this high-stakes therapeutic area provide a clear performance benchmark for investors, and the latest results clearly favored Eli Lilly. The market's response was swift and negative.

Reflecting this shift in sentiment, Novo Nordisk's share price has retreated to €33.73, marking a new 52-week low. In light of the trial outcome, analysts at Deutsche Bank revised their rating on the company's stock, moving it from "Buy" to "Hold."

Path Forward for CagriSema Remains Intact

Despite this specific trial result, the development pathway for CagriSema is not terminated. Novo Nordisk has already submitted the drug for regulatory approval to the U.S. Food and Drug Administration (FDA). This submission is based on data from other pivotal studies, and a decision from the agency is anticipated by the end of 2026.

Furthermore, the company has outlined plans to initiate a new Phase 3 study featuring a higher dosage in the second half of 2026. This move signals a clear intention to strengthen the drug's clinical profile rather than abandon the project, indicating ongoing commitment to competing in the obesity treatment arena.